Exhibiting at VIV Asia 2025

MedFluid Co., Ltd., based in Zhubei City, Hsinchu County, Taiwan, is an innovative biotech company pioneering microfluidic-based diagnostic solutions. With a mission to revolutionize point-of-care testing and tackle global challenges like antimicrobial resistance, MedFluid develops compact, rapid, and precise diagnostic platforms that support early pathogen detection and informed antibiotic use in clinical, veterinary, and environmental applications.

Core Business

MedFluid specializes in the research, development, and commercialization of microfluidic lab-on-chip diagnostic platforms. The company combines cutting-edge microfluidics, molecular diagnostics, and artificial intelligence (AI) to produce portable devices that provide laboratory-level diagnostic performance at the point of care.

MedFluid’s systems are built for on-site, real-time pathogen detection and antimicrobial susceptibility testing (AST), helping medical professionals make timely and accurate treatment decisions.

Product & Service Offerings

MedFluid’s flagship innovations include two integrated diagnostic platforms:

• O-in (On-site Integrated Nucleic Acid Testing System)

  • A compact, point-of-care molecular diagnostics device
  • Delivers rapid PCR-based pathogen identification in 25 minutes
  • Designed for use in human and veterinary medicine, food safety, and environmental monitoring
  • Single-button operation and portable format for field deployment
  • Compatible with multiple sample types (blood, swabs, sputum, urine, etc.)

• NAST (Nest-shape Antimicrobial Susceptibility Testing)

  • A microfluidic AST platform to determine bacterial drug resistance
  • Provides phenotypic antibiotic susceptibility results within 3 hours
  • Ideal for clinical settings requiring urgent treatment guidance
  • Aids in combating antimicrobial resistance (AMR) by promoting targeted antibiotic usage
  • Disposable microfluidic cartridges ensure sterility and test reliability

These products are supported by a cloud-based software infrastructure for data recording, analysis, and AI-driven insights.

Specialisation and USP

MedFluid's competitive advantage is grounded in its proprietary microfluidic technology that allows:

• Miniaturization of laboratory assays into portable, disposable test cartridges
• Significantly shorter detection and AST timeframes compared to traditional culture methods
• Ease of use through automation and one-step testing interfaces
• Integration with AI algorithms to enhance diagnostic accuracy and interpret complex results

By combining these features, MedFluid delivers solutions that address urgent public health and clinical needs, especially in decentralized and resource-limited settings.

Financial Strength

As a rapidly scaling medical diagnostics company, MedFluid has secured funding through government innovation programs, private investors, and strategic partnerships. The company has been recognized in Taiwan's biomedical innovation sector and has participated in multiple startup incubators and accelerators, including:

• Taiwan Tech Arena (TTA)
• InnoVEX at COMPUTEX
• Bio Asia Taiwan

These achievements demonstrate its financial viability and investor confidence in its technology roadmap.

Shipment Data

While commercial deployment is still scaling, MedFluid has:

• Piloted O-in systems in hospitals and clinics across Taiwan and Southeast Asia
• Deployed NAST platforms for research collaborations with infectious disease laboratories
• Secured validation contracts for veterinary and environmental use-cases

Export expansion is underway in Japan, South Korea, and ASEAN markets, targeting point-of-care testing applications in both urban and rural settings.

Target Market

MedFluid targets a diverse range of sectors seeking rapid, accurate, and portable diagnostic capabilities:

• Human healthcare (clinics, hospitals, emergency care units)
• Veterinary medicine (farm-level diagnostics, companion animal care)
• Environmental surveillance (water testing, foodborne pathogen detection)
• Pharmaceutical R&D (antibiotic development, clinical trials)

Customers include diagnostics laboratories, public health agencies, biotech firms, and veterinary service providers.

Capabilities

MedFluid has developed a vertically integrated capability structure that spans:

• Microfluidic chip design and mass production
• In-house reagent formulation and lyophilization
• PCR protocol development and pathogen panel customization
• System prototyping and clinical validation
• Regulatory affairs and clinical trial coordination

The company also offers customizable diagnostic kits for partners in pharmaceutical, academic, and governmental sectors.

Certifications and Compliance

MedFluid is actively pursuing and operating under internationally recognized certifications:

• ISO 13485 for medical device quality management systems
• CE marking underway for O-in and NAST platforms
• Compliance with IVD regulations in Taiwan, and planning future entry into the U.S. FDA 510(k) and EU IVDR frameworks
• All devices built to biosafety and sterile testing standards required for diagnostic instrumentation

These certifications ensure global market readiness and user confidence.

Major Achievements

• Developed O-in, a PCR-based diagnostic platform capable of delivering results in under 30 minutes
• Reduced traditional AST turnaround times from 2-3 days to under 3 hours with NAST
• Recognized by Taiwan’s Ministry of Science and Technology for innovation in infectious disease management
• Partnered with hospitals and research labs for clinical trials and AMR surveillance programs
• Selected to represent Taiwan’s MedTech sector at international biotech expos

Customer Testimonials

Pilot users and clinical partners report:

• High accuracy of pathogen detection and AST results
• Remarkable time savings in critical care scenarios
• User-friendly design that requires minimal technical training
• Significant potential for decentralized diagnostics and rural healthcare deployment

MedFluid continues to lead the next generation of portable, real-time diagnostics with scalable solutions aimed at empowering clinicians, curbing antimicrobial resistance, and enhancing global health preparedness.